16.77 0.00 (0.00%)
After hours: 4:36PM EDT
|Bid||16.75 x 2200|
|Ask||16.76 x 900|
|Day's Range||16.52 - 16.94|
|52 Week Range||11.31 - 33.13|
|Beta (3Y Monthly)||3.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...
Insmed (INSM) delivered earnings and revenue surprises of 4.71% and 20.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Chairman, President & CEO of Insmed Inc (NASDAQ:INSM) William Lewis sold 400,000 shares of INSM on 06/25/2019 at an average price of $26 a share.
Insmed Inc NASDAQ/NGS:INSMView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for INSM with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 11. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding INSM are favorable, with net inflows of $2.18 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Is Insmed Incorporated (NASDAQ:INSM) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]
In 2012 Will Lewis was appointed CEO of Insmed Incorporated (NASDAQ:INSM). This report will, first, examine the CEO...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 20) Kaleido Biosciences Inc (NASDAQ: KLDO ) Down In The ...
Insmed (INSM) delivered earnings and revenue surprises of 0.00% and 0.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of 96 cents. Losses, adjusted for amortization costs, were 94 cents per share. The results met Wall Street expectations. ...
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of December 31st. In this article we look at what those investors think of Insmed Incorporated (NASDAQ:INSM). Is Insmed Incorporated (NASDAQ:INSM) […]
How far off is Insmed Incorporated (NASDAQ:INSM) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the foreast future cash flows of the company and dis...
Insmed (INSM) delivered earnings and revenue surprises of -5.41% and 96.19%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?